03106nam 22007094a 450 991045073980332120200520144314.01-135-62813-01-282-32386-597866123238671-4106-1274-0(CKB)1000000000244710(EBL)227528(OCoLC)475934668(SSID)ssj0000216265(PQKBManifestationID)11166480(PQKBTitleCode)TC0000216265(PQKBWorkID)10195179(PQKB)11472707(MiAaPQ)EBC227528(Au-PeEL)EBL227528(CaPaEBR)ebr10110060(EXLCZ)99100000000024471020030922d2005 uy 0engur|n|---|||||txtccrOrganized activities as contexts of development[electronic resource] extracurricular activities, after-school, and community programs /edited by Joseph L. Mahoney, Reed W. Larson, Jacquelynne S. EcclesMahwah, NJ Lawrence Erlbaum20051 online resource (565 p.)Description based upon print version of record.0-8058-4431-7 0-8058-4430-9 Includes bibliographical references and indexes.Contents; Foreword: Promoting Positive Youth Development Through Community and After-School Programs; I: SOCIAL AND CULTURAL PERSPECTIVES; II: DEVELOPMENTAL PROCESSES AND OUTCOMES; III: INTEGRATING RESEARCH, PRACTICE, AND POLICY; About the Editors; About the Authors; Author Index; Subject IndexSchool-aged children in the U.S. and other Western nations spend almost half of their waking hours in leisure activities. For some, out-of-school time is perceived as inconsequential or even counterproductive to the health and well-being of young persons. Recently, however, there has been a growing recognition that--along with family, peers, and school--the organized activities in which some youth participate during these hours are important contexts of emotional, social, and civic development. They provide opportunities for young persons to learn and develop competencies that are largely neglStudent activitiesUnited StatesStudentsServices forUnited StatesCommunity and schoolUnited StatesChild developmentUnited StatesYouthAdolescenceElectronic books.Student activitiesStudentsServices forCommunity and schoolChild developmentYouth.Adolescence.371.8/9Mahoney Joseph L964393Larson Reed1950-964394Eccles Jacquelynne S948931MiAaPQMiAaPQMiAaPQBOOK9910450739803321Organized activities as contexts of development2187520UNINA05074oam 2200637I 450 991045885390332120200520144314.00-429-14207-21-58488-918-710.1201/EBK1584889175 (CKB)2670000000033117(EBL)555711(OCoLC)652654235(SSID)ssj0000414237(PQKBManifestationID)11307058(PQKBTitleCode)TC0000414237(PQKBWorkID)10401383(PQKB)10085636(MiAaPQ)EBC555711(Au-PeEL)EBL555711(CaPaEBR)ebr10405036(CaONFJC)MIL694454(EXLCZ)99267000000003311720180331d2011 uy 0engur|n|---|||||txtccrClinical trial methodology /Karl E. Peace, Ding-Geng (Din) ChenBoca Raton :Chapman and Hall/CRC Press,2011.1 online resource (422 p.)Chapman & Hall/CRC biostatistics series ;35Description based upon print version of record.1-322-63172-7 1-58488-917-9 Includes bibliographical references and index.Front cover; Contents; Preface; Chapter 1: Overview of Clinical Trial Methodology; Chapter 2: Overview of the Drug Development Processand Regulation of Clinical Trials; Chapter 3: Ethical Considerations in the Designand Conduct of Clinical Trials; Chapter 4: Sample Size Considerations in ClinicalTrials Pre-Market Approval; Chapter 5: Sequential, Group Sequential, StochasticCurtailment, and Adaptive DesignProcedures in Clinical Trials; Chapter 6: Biostatistical Aspects of the Protocol; Chapter 7: The Statistical Analysis Plan; Chapter 8: Pooling of Data from Multicenter Clinical TrialsChapter 9: Validity of Statistical InferenceChapter 10: Bioequivalence Clinical Trials; Chapter 11: Dose and Frequency Determinationfrom Phase II Clinical Trials in StressTest-Induced Angina; Chapter 12: Confirmation of Clinically Optimal Dosingin the Treatment of Duodenal Ulcers:A Phase III Dose Comparison Trial; Chapter 13: Pivotal Proof-of-Efficacy Clinical Trialsin the Prevention of NANSAID-InducedGastric Ulceration; Chapter 14: Clinical Trials in the Treatmentof Alzheimer's Disease Based uponEnrichment Designs; Chapter 15: A Clinical Trial to Establish Reductionof CHD RiskChapter 16: Pivotal Proof-of-Efficacy Clinical Trialsin the Treatment of Panic DisorderChapter 17: Combination Clinical Trials; Chapter 18: Monitoring Clinical Trials for Adverse Events; Index; Back coverNow viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial. Drawing from the authors courses on the subject as well as the first authors more than 30 years working in the pharmaceutical industry, Clinical Trial Methodology emphasizes the importance of statistical thinking in clinical research and presents the methodology as a key component of clinical research. From ethical issues and sample size considerations to adaptive design procedures and statistical analysis, the book first covers the methodology that spans every clinical trial regardless of the area of application. Crucial to the generic drug industry, bioequivalence clinical trials are then discussed. The authors describe a parallel bioequivalence clinical trial of six formulations incorporating group sequential procedures that permit sample size re-estimation. The final chapters incorporate real-world case studies of clinical trials from the authors own experiences. These examples include a landmark Phase III clinical trial involving the treatment of duodenal ulcers and Phase III clinical trials that contributed to the first drug approved for the treatment of Alzheimers disease. Aided by the U.S. FDA, the U.S. National Institutes of Health, the pharmaceutical industry, and academia, the area of clinical trial methodology has evolved over the last six decades into a scientific discipline. This guide explores the processes essential for developing and conducting a quality clinical trial protocol and providing quality data collection, biostatistical analyses, and a clinical study report, all while maintaining the highest standards of ethics and excellence--Provided by publisher.Chapman & Hall/CRC biostatistics series ;35.Clinical trialsDrugsTestingElectronic books.Clinical trials.DrugsTesting.615.5072/4Peace Karl E.1941,863165Chen Ding-Geng863166FlBoTFGFlBoTFGBOOK9910458853903321Clinical trial methodology1926880UNINA01266oam 2200421zu 450 991016429180332120210807002055.00-8031-6768-7(CKB)3170000000044502(SSID)ssj0001490593(PQKBManifestationID)11829637(PQKBTitleCode)TC0001490593(PQKBWorkID)11476420(PQKB)11137375(NjHacI)993170000000044502(EXLCZ)99317000000004450220160829d1955 uy engur|||||||||||txtccrSymposium on Coal Sampling[Place of publication not identified]American Society for Testing & Materials19551 online resource (152 pages)ASTM special technical publication ;162Bibliographic Level Mode of Issuance: Monograph0-8031-6532-3 ASTM special technical publication ;162.CoalAnalysisCoalAnalysis.662.622Anderson W866011PQKBBOOK9910164291803321Symposium on Coal Sampling1932758UNINA00968nam 2200349 450 991082894240332120230817181446.01-5475-9752-6(CKB)4100000008780108(MiAaPQ)EBC5838211(EXLCZ)99410000000878010820190911d2019 uy 0gerurcnu||||||||txtrdacontentcrdamediacrrdacarrierMomo Traders /Brady Dahl ; traduit par Giovanni Pantano[Place of publication not identified] :Babelcube Books,2019.1 online resource (218 pages)Building tradesBuilding trades.690.023Dahl Brady1706518Pantano GiovanniMiAaPQMiAaPQMiAaPQBOOK9910828942403321Momo Traders4093985UNINA